Audit: QRS - Lacticaseibacillus paracasei for Health & Longevity
Audit conducted on 05/09/2026 03:48 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: at-a-glance vs ER Conclusion (498-502), protocol cells vs ER 371/373/381, time cells vs ER 430/188, benefit and risk items vs the ER tier headings, all 7 markers vs the ER table (462-468), cadence vs ER 458, qualitative items vs ER 472-476. All literally supported. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing carried over: “Shorter courses have not shown these effects” (ER 373), “morning against evening has not been compared” (ER 381 “no trial has compared morning against evening dosing”), “Nothing in the trial record supports judging a course before four weeks have passed” (ER 430). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening. Contraindication thresholds (ANC < 0.5 x 10^9/L, CD4 < 200 cells/uL, revised Atlanta severe or moderately severe, 12-month transplant window) are all carried at ER strength. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Categories are preserved: ER contraindication population list (345-351) -> Contraindications gate; ER caution/monitor interactions (327-341) -> Key Interactions gate; ER benefit and risk tiers -> matching QRS tiers. No Benefit- or Risk-Modifying Factor is surfaced as a gate item. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, expert names or years appear. The only named entity is the Shirota strain, which the ER uses for the same facts (ER 371 dose, ER 188 cortisol). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution appears that is not in the ER for the same fact. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Tone tracks the ER: sponsor-linked, strain-specific, hedged framing is preserved in the at-a-glance and in the protocol subs. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert, objective and data-driven (numeric doses, thresholds, biomarker targets) while remaining accessible; the sheet gives the reader a usable execution frame. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence-derived parameters rather than instructions to a patient; no clinician voice. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No diagnostic or treatment advice. The only imperative-mood text is the Cadence line, which mirrors ER 458 verbatim in framing, and the fixed template disclaimer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content is presented as findings and parameters; scan for “should/recommend/advise/must/consider/ensure” returns no hits in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun anywhere in the sheet body (scan for you/your/yours returns zero hits). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; retained technical terms (absolute neutrophil count, revised Atlanta, atherogenic lipids) are load-bearing decision thresholds required by 8.5 and the ER monitoring table. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every item is compressed to the key fact; parentheticals, mechanisms and effect sizes from the ER are stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address to the reader. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal functional biomarker targets (hs-CRP < 0.5 mg/L, LDL-C < 80 mg/dL, HbA1c 4.8-5.2 %) rather than conventional reference ranges signal the longevity-oriented audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents a 4-to-12-week minimum course, daily dosing, seasonal symptom tracking and a repeat lab panel at 12 weeks - effortful protocol elements. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not written for the general population; assumes willingness to track biomarkers and run a multi-month course. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting reflects the audience: the sheet foregrounds the strain-code caveat and the safety gate rather than a generic “probiotics are healthy” framing. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging” anywhere in the document. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology in the document’s own voice (adverse categories, “gastrointestinal symptoms”, “allergic rhinitis”, “absolute neutrophil count”). The plain-language wording in the at-a-glance (“stomach infections”, “hay-fever symptoms”) is required by 7.4 and is verbatim ER Conclusion phrasing. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings present unmodified: “Protocol” (446), “Time to effect” (492), “Benefits” (541), “Risk & Side Effects” (613), “Monitoring” (636), “Qualitative Assessment” (753), “Contraindications” (572), “Key Interactions” (592), tier labels High/Medium/Low/Speculative, and Marker/Target/Why (640-642). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables present; the repeatable marker_#* and qualitative_item# spans are expanded to marker_1..7 and qualitative_item_1..5. Diff against the template shows no missing span. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff of lines 15-411 against the template head/style block is byte-identical apart from the title; the website=”evidence_review”, website=”audit” and website=”full_review” spans and the footer disclaimer are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section that maps to a QRS variable is empty. The one empty tier (ER “Medium” risks, line 285) is governed by the more specific rule 13.5, which requires display:none rather than empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels reused verbatim: “Standard dose”, “Minimum duration before judging”, “Best time of day” (ER 371/373/381); interaction labels “Systemic antibiotics”, “Proton pump inhibitors”, “Lipid-lowering agents”, “Supplements with additive effects”, “Prebiotic fibres”, “Other interventions” (ER 327-341); all 7 marker names verbatim from the ER table. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label is paraphrased or invented. The three Time-to-Effect labels are lifted from the ER’s own wording at line 430 (“lipid, inflammatory and muscle endpoints”, “stress endpoints”, “bowel-habit”). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators anywhere; the ER’s tier emojis and the “Conflicted” warning marks are stripped. Tier emphasis is carried by the labels and CSS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Each section is condensed to the per-section budget rather than dumped: 8 low-tier benefits compressed to a single semicolon-separated line, ER parentheticals and mechanism clauses removed, marker “Context/Notes” column dropped entirely. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment occupies lines 1-13, immediately after <!doctype html> and before any other comment or markup. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 2 and closing “—” at line 12; the preceding “QRS - Metadata (invisible, parsed by audit tooling)” text is permitted. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element on the sheet surfaces any of these values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed. Only duration: “00:03” is quoted, and it contains a colon, which requires YAML quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: lacticaseibacillus_paracasei_2026-0905-0008_Opus_ER.md, matching the source ER’s own filename frontmatter field. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0905-0334, in YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname plus version number, no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: lacticaseibacillus_paracasei_2026-0905-0008_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed clean and consistent; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic = “Lacticaseibacillus paracasei for Health & Longevity” (line 417), matching canonical_topic in the ER frontmatter. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date = 09/05/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0905-0334. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model = “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; no badge, version stamp, AKA line, audit date or variant marker. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (498-502): commercial history and sponsor entanglement, the two clearest outcome domains, and the execution-critical strain-code caveat. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words, counted programmatically. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to a distinct ER Conclusion passage: line 498 for the history/breadth and the two clearest findings, line 502 for the strain-code point. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms and no specialist classifications: “fermentation bacterium”, “stomach infections”, “hay-fever symptoms”, “named strain” are all plain-language. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ER’s “Populations who should avoid Lacticaseibacillus paracasei” list inside Key Interactions & Contraindications (ER 343-351). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 7 ER contraindication populations are represented, one-for-one, with no additions. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the stop_items span (lines 575-587). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is reduced to the key fact; the ER’s “People with …” stem and the CD4 gloss “(a measure of the immune cells the virus destroys)” are dropped. No trailing dash clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Decision-relevant qualifiers preserved: “below 0.5 x 10^9/L”, “within 12 months”, “(revised Atlanta severe or moderately severe)”, “below 200 cells/uL”, “in place for parenteral nutrition”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication list; the one graded qualifier is spelled out as “severe or moderately severe”. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is not empty, and the ER does identify populations that should avoid the intervention, so the emptiness constraint is satisfied. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ER Key Interactions & Contraindications bullets (ER 327-341). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Six of the ER’s eight interaction bullets are carried. The two omitted - immunosuppressants/biologics and cytotoxic chemotherapy causing neutropenia - are flagged “Absolute contraindication” in the ER and are already covered by the stop items “ongoing high-dose immunosuppression” and “Absolute neutrophil count below 0.5 x 10^9/L”. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the caution_items span (lines 595-603). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is label plus example list only; the ER’s mechanism and mitigation text (“Separating doses by at least two hours …”, “starting the fibre at a quarter dose …”) is stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs preserved for every item: amoxicillin/clarithromycin/ciprofloxacin; omeprazole/pantoprazole; statins/ezetimibe/bile acid sequestrants; soluble fibre/psyllium/plant sterols/red yeast rice/berberine/other probiotic species; inulin/galacto-oligosaccharides; faecal microbiota transplantation/elemental diets. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is not empty, and the ER does identify interactions that change how the intervention is used, so the emptiness constraint is satisfied. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (ER 369-395). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard dose, minimum duration before judging, and best time of day are the three most actionable implementation parameters in the ER Protocol section. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three actionable implementation aspects; all three action sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content: the dose range and its trial provenance (ER 371), the 4-to-12-week window (ER 373), and meal-timing with the gastric-acid rationale (ER 381). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER’s Time to effect bullet (ER 430) names three endpoint domains - lipid/inflammatory/muscle, stress, and bowel habit - and all three are represented. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered by benefit magnitude: lipid/inflammatory/muscle and stress are Medium-tier ER benefits and come first; bowel habit is a Low-tier ER benefit and comes last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content: the 12-week and 4-to-8-week windows from ER 430, the eight-week Shirota cortisol result from ER 188, and the four-week floor from ER 430. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 430), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (ER 154-253). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit spans present and populated (lines 543-565). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER’s own H4 benefit heading and nothing more; no effect sizes, mechanisms, trial details or attributions carried through. Retained scope words (“in older adults”, “after perinatal use”) are part of the ER heading and removing them would broaden the claim. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | All parenthetical content stripped: the ER’s “(eczema)”, “(a pooling ranking treatments indirectly)”, “(chronic bad breath)” and every Magnitude paragraph are absent. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry items in the ER (2 high, 4 medium, 8 low, 1 speculative), so no span needs to be hidden. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (ER 271-309). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk spans present (lines 615-630). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER’s own H4 risk heading; the pooled RR, the case-survey detail and the mechanism text are all absent. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | All parenthetical content stripped, including “(bacteria in the bloodstream)”, “(infection of the heart lining)” and “(excess bacteria in the small bowel)”. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER’s Medium tier carries no risk (ER 285, “No risk reaches Medium”), and risks_medium is correctly set to style=”display: none” with empty content (line 618) rather than empty-state phrasing. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (ER 456-468). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 7 rows of the ER biomarker table are present with matching names, targets and rationales: hs-CRP, interleukin-6, LDL cholesterol, remnant cholesterol, triglycerides, HbA1c, absolute neutrophil count. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | monitoring_cadence populated from ER 458: repeat lipids and inflammatory markers at 12 weeks, then 6-to-12-month intervals if the course continues, with daily symptom tracking for two weeks and weekly thereafter. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER’s qualitative marker list in Monitoring Protocol & Defining Success (ER 470-476). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 5 ER qualitative markers listed: Bristol Stool Form Scale target, daily GI symptom log, seasonal infection frequency and duration, afternoon alertness and perceived stress, and lower-limb function over 65. |
Issues 05/09/2026 03:48
Pass rate 100.00%. No issues found.
Issues 05/09/2026 03:40
- 7.2 — At-a-glance exceeds word limit: The [at_a_glance] text at lines 434-438 is 61 words, one over the 60-word maximum.
Fixes 05/09/2026 03:40
- 7.2 — At-a-glance trimmed under word cap: Reduced [at_a_glance] from 61 to 59 words by dropping “closely” and condensing “belongs to one named strain rather than the species” to “belongs to a named strain, not the species”.